Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 21, 2015; 21(35): 10234-10241
Published online Sep 21, 2015. doi: 10.3748/wjg.v21.i35.10234
Published online Sep 21, 2015. doi: 10.3748/wjg.v21.i35.10234
Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication
Jae Jin Hwang, Dong Ho Lee, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Nayoung Kim, Department of Internal medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do 463-707, South Korea
Author contributions: Hwang JJ and Lee DH were responsible for the study conception and design, data analysis and interpretation, and manuscript drafting; Yoon H, Shin CM, Park YS, and Kim N critically revised the article for important intellectual content; all the authors reviewed and approved the final version to be published.
Institutional review board statement: The study was reviewed and approved by the Seoul National University Bundang Hospital Institutional Review Board.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare no conflict of interests.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dong Ho Lee, MD, Department of Internal Medicine, Seoul National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam, Gyeonggi-do 463-707, South Korea. dhljohn@yahoo.co.kr
Telephone: +82-31-7877006 Fax: +82-31-7874051
Received: April 10, 2015
Peer-review started: April 10, 2015
First decision: May 18, 2015
Revised: June 2, 2015
Accepted: July 8, 2015
Article in press: July 8, 2015
Published online: September 21, 2015
Processing time: 161 Days and 2.6 Hours
Peer-review started: April 10, 2015
First decision: May 18, 2015
Revised: June 2, 2015
Accepted: July 8, 2015
Article in press: July 8, 2015
Published online: September 21, 2015
Processing time: 161 Days and 2.6 Hours
Core Tip
Core tip: To our knowledge, this is the first study to evaluate the efficacy of 14-d treatment with moxifloxacin-based sequential therapy compared with hybrid therapy as a first-line treatment for Helicobacter pylori (H. pylori) infection. Our study shows that moxifloxacin-based sequential therapy is more effective with fewer adverse events compared with hybrid therapy. The high rates of H. pylori eradication and patient compliance with treatment, and low rate of adverse events seen here suggest that moxifloxacin-based sequential therapy is a suitable alternative to standard triple therapy.